









Markets
/
Stocks
/
nasdaq-dxr
/

Daxor Corp

DXR

11.880USD

+0.480+4.21%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

59.22MMarket Cap

--P/E TTM



Daxor Corp

11.880

+0.480+4.21%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

25 / 30

Overall Ranking

329 / 4720

Industry

Collective Investments

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

23.500

Target Price

+106.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.22M.

Overvalued

The company’s latest PB is 1.64, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.92M shares, decreasing 0.28% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 49.03K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Collective Investments industry's average is 7.25. Its latest quarterly revenue reached 3.41M, representing a year-over-year decrease of 11.46%, while its net profit experienced a year-over-year decrease of 34.68%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 4.00, which is lower than the Collective Investments industry's average of 4.36. Its current P/E ratio is 104.88, which is -15.35% below the recent high of 88.78 and 24.04% above the recent low of 79.67.

Score

Industry at a Glance

Previous score

4.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 25/30

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Collective Investments industry's average of 6.95. The average price target for Daxor Corp is 23.50, with a high of 25.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

23.500

Target Price

+106.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Daxor Corp

DXR

Sixth Street Specialty Lending Inc

TSLX

FS KKR Capital Corp

FSK

SLR Investment Corp

SLRC

PennantPark Floating Rate Capital Ltd

PFLT

Gladstone Capital Corp

GLAD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.98, which is higher than the Collective Investments industry's average of 7.26. Sideways: Currently, the stock price is trading between the resistance level at 12.07 and the support level at 10.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.98

Change

0.35

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.014

Buy

RSI(14)

62.356

Neutral

STOCH(KDJ)(9,3,3)

84.220

Neutral

ATR(14)

0.482

Low Volatility

CCI(14)

108.405

Buy

Williams %R

0.000

Overbought

TRIX(12,20)

0.400

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

11.555

Buy

MA10

11.472

Buy

MA20

11.224

Buy

MA50

10.500

Buy

MA100

9.502

Buy

MA200

8.688

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is higher than the Collective Investments industry's average of 3.77. The latest institutional shareholding proportion is 58.85%, representing a quarter-over-quarter decrease of 1.94%. The largest institutional shareholder is The Vanguard, holding a total of 49.03K shares, representing 0.98% of shares outstanding, with 0.61% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Joseph Feldschuh UEO

2.55M

Feldschuh (Michael Richard)

212.69K

+1.50%

The Vanguard Group, Inc.

Star Investors

49.03K

+0.41%

Feldschuh (Jonathan Adam)

35.91K

Renaissance Technologies LLC

Star Investors

28.12K

+1.08%

Michel (Robert J)

17.05K

+38.62%

Keyes Stange & Wooten Wealth Management LLC

15.91K

+8.91%

Morgan Stanley Smith Barney LLC

87.00

-1.14%

Desrosiers (Caleb J.D.)

3.16K

SBI Securities Co., Ltd.

3.13K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.91, which is lower than the Collective Investments industry's average of 5.31. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.